Veeva Systems(NYSE) VEEV

Veeva makes cloud software for the global life sciences industry. Its tools help drug companies develop new medicines faster. The company also helps firms market products and follow regulations.

Cloud Software for Healthcare

• R&D and Quality Solutions: Software for clinical research and manufacturing compliance; accounts for 55% of revenue.
• Commercial Solutions: Tools for customer relationship management and marketing analytics; accounts for 45% of revenue.
• Subscription Services: Internet-based access to software applications and industry data; represents 83% of revenue.
• Professional Services: Business consulting and technical support for system implementation; represents 17% of revenue.

Recent Strategic Moves

• Acquired Ostro (Rise Healthcare Tech, Inc.) on March 9, 2026, for $90 million to add AI-driven patient engagement tools.
• Integrated Ostro technology to provide immediate, compliant answers to medical questions through an artificial intelligence chat platform.
• Launched Veeva AI to integrate intelligent agents across the Vault software platform and commercial application suites.
• Transitioned employee long-term incentives from annual stock option grants to restricted stock units in April 2026.

How Veeva Serves Drugmakers

Veeva provides a specialized cloud platform for the life sciences industry. Its software helps companies maintain regulatory compliance while managing the end-to-end process of drug development.

The Financial Scorecard

• Total revenue reached $882.9 million in Q1 2027, up 16.3% year-over-year.
• Net income hit $260.9 million in the quarter ended April 30, 2026, up 14.4% from the prior year.
• Operating cash flow reached $1.1 billion in Q1 2027, a 28.5% increase from Q1 2026.
• Gross profit rose to $662 million in Q1 2027, up 13.1% from the previous year.
• Research and development spending grew to $208.3 million in Q1 2027 to enhance core software platforms.

Evolution of the Business

Veeva has evolved from a sales-focused software firm into a comprehensive platform for the entire drug lifecycle. Its growth in research and development tools has diversified its revenue and deepened its role in the life sciences industry.